Peter Fan founded Willingjet in 2002, leveraging two decades of experience in leading pharmaceutical MNCs. His passion for new drug development and language translation drove the company to excel in delivering exceptional services to the pharmaceutical, clinical, medical device, and biotech industries. Over the years, Willingjet has expanded its capabilities to offer a comprehensive range of services including translation, MTPE, interpretation, regulatory review, localization, copywriting, regulatory operations, IP services, and more. With a team proficient in over 100 languages, with a focus on Asian languages, we are positioned as your premier global communication partner.
At Willingjet, we pride ourselves on providing value-driven solutions that transcend mere transactions to achieve strategic outcomes aligned with your organizational goals. Our commitment to swift project delivery ensures urgent timelines are met without compromising quality. Backed by a team of seasoned translators and subject-matter experts deeply versed in the medical industry, we uphold rigorous standards of quality. Willingjet holds certifications in ISO 9001, ISO 17100, and ISO 13485, underscoring our steadfast commitment to excellence. Furthermore, our emphasis on technological innovation enhances the precision and efficiency of our services.
By choosing Willingjet as your partner, you are selecting more than just a translation service; you are opting for a comprehensive solution that combines regulatory expertise with cutting-edge technology. Our holistic approach ensures that your message is not only accurately translated but also strategically aligned with global compliance and market needs. Let Willingjet guide you through the complexities of global market expansion, ensuring your voice is clearly understood and translated across borders with confidence.
Our experts have a deep understanding of the challenges, requirements and regulations of the life science industry. Willingjet, a premier translation service company, offers top-notch translation solutions tailored to your business needs. Our expert linguists ensure accurate, culturally relevant translations, enhancing global communication. Trust Willingjet for seamless, professional translation services that bridge language barriers and drive international success.
Peter Fan is a distinguished expert in the medical industry, with a career spanning over three decades. Beginning as an Associate Researcher at the Cancer Research Institute, his work on pivotal cancer research projects earned him significant recognition. Later, Peter took on key roles in the pharmaceutical sector, including Medical Manager at Sanofi and Training Manager at Novartis, where he added considerable value. In 2002, he founded Willingjet, offering specialized translation and localization services to prominent life sciences brands. He holds an MBA and a Bachelor's degree in Environmental Chemistry.
Michael is a prominent figure in the medical translation industry with an extensive background in drug regulatory affairs. Co-founding Willingjet Life Science in 2002, he has significantly contributed to supporting drug development with professional translation and global language services. His technical expertise also led him to pioneer translation technologies, aiming to continuously improve efficiency and quality. Michael's academic foundation is with two Bachelor's degrees—one in Business Administration and another in English Language and Literature.
As the Head of US Operations and an early Angel Investor, Alex recognized the potential of the life science and clinical translation industry, playing a key role in the company’s successful launch in the United States. With extensive experience in clinical research, Alex has made significant contributions to sectors including clinical supply, AI-driven SaaS platforms, and medical devices. Fluent in English, French, Italian, German, and Spanish, he effectively connects with diverse stakeholders. Alex holds a double master's degree in international economics and international affairs.
Elke Paris is the Director of EMEA Operations at Willingjet Life Science, bringing over three decades of experience to the role. Her expertise spans linguistics, regulations, and strategic consulting, with a particular focus on the pharmaceutical sector in Europe. As a seasoned professional in medical translation and review, Elke excels in facilitating product development and connecting clients with regulatory professionals across Europe.
Yu Dian has been living and working in Japan for over 15 years, bringing more than a decade of expertise in Japanese translation and interpretation, particularly within the medical and pharmaceutical sectors. With over three years of project and account management experience with local Japanese clients, Yu currently oversees Willingjet’s Japan office. In this role, Yu manages both in-house and freelance translators, ensuring the highest quality of translation services for our clients in Japan.
Currently leading the eCTD Team at Willingjet Life Sciences, is an expert in electronic submissions for pharmaceuticals. His tenure at Pfizer as a Publishing Team Lead and PPLS Manager honed his skills in document publishing and management for drug regulatory processes. Richard's educational background includes a Master's in Medicinal and Pharmaceutical Chemistry and a Bachelor's in Traditional Chinese Medicine. This blend of technical expertise and academic knowledge makes him a key player in Willingjet's focus on enhancing electronic submission strategies in the pharmaceutical sector.
Angelika can look back on a career in linguistic consulting and management, spanning over 30 years and several countries, among them Ireland, Germany, Italy, China and Singapore. She brings a wealth of knowledge in translation, language evaluation, and quality management. Her deep understanding of localization processes and her ability to manage multilingual teams have made her a sought-after specialist in the industry. With a strong focus on delivering high-quality language services, Angelika continues to contribute significantly to the field of linguistic management.
06 09 2024
EN 
cn 
de 
jp 
